검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | CAR-T cell immunotherapy |
Overview Company | Shenzhen BinDeBio Ltd. |
Overview Modality | CGT |
Overview Target | GD2 |
Overview Indication | B-cell Acute Lymphoblastic Leukemia; Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | CAR-T cell functionality required genetic ablation of STING in CAR-T cells and was dependent on cancer cell-intrinsic STING signaling on STING-agonistic treatment |
MoA Biomarker | biomarker that may help individualized risk stratification and inform treatment optimization in CAR-T therapy |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Manganese-tannic acid immunomodulators potentiate PDGFRβ CAR-T cell function for additive therapy against liver fibrosis.. Chimeric antigen receptor (CAR)-T cell therapy has achieved considerable success in treating malignant tumors. However, its therapeutic efficacy in hepatic fibrosis remains unclear. The activated hepatic stellate cells (aHSCs) represent a central driver in the initiation… |
Toxicology CRS | grade 3 |
Clinical Primary efficacy | ORR 80.3% |
Clinical ORR | 80.3% |
Clinical PFS | 9.03 |
Clinical OS | NA |
Clinical Result source | ClinicalTrials.gov NCT03483103 |
Clinical Data Tier / Score | A · 68 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | CAR-T cell immunotherapy |
Overview Company | Shenzhen BinDeBio Ltd. |
Overview Modality | CGT |
Overview Target | GD2 |
Overview Indication | B-cell Acute Lymphoblastic Leukemia; Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | CAR-T cell functionality required genetic ablation of STING in CAR-T cells and was dependent on cancer cell-intrinsic STING signaling on STING-agonistic treatment |
MoA Biomarker | biomarker that may help individualized risk stratification and inform treatment optimization in CAR-T therapy |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Manganese-tannic acid immunomodulators potentiate PDGFRβ CAR-T cell function for additive therapy against liver fibrosis.. Chimeric antigen receptor (CAR)-T cell therapy has achieved considerable success in treating malignant tumors. However, its therapeutic efficacy in hepatic fibrosis remains unclear. The activated hepatic stellate cells (aHSCs) represent a central driver in the initiation… |
Toxicology CRS | grade 3 |
Clinical Primary efficacy | ORR 80.3% |
Clinical ORR | 80.3% |
Clinical PFS | 9.03 |
Clinical OS | NA |
Clinical Result source | ClinicalTrials.gov NCT03483103 |
Clinical Data Tier / Score | A · 68 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
추천 비교
추천 비교